Racial and Treatment Center Differences on Time to Treatment Initiation for Nonsmall Cell Lung Cancer Patients Receiving Radiation Therapy As an Initial Treatment.
United States
lung cancer
racial disparities
time to treatment
treatment facilities
Journal
Health equity
ISSN: 2473-1242
Titre abrégé: Health Equity
Pays: United States
ID NLM: 101708316
Informations de publication
Date de publication:
2022
2022
Historique:
accepted:
20
07
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
10
9
2022
Statut:
epublish
Résumé
Because time to treatment has been shown to be associated with increase in the risk of death for Non Small Cell Lung Cancer (NSCLC) patients, we examined the prevalence and magnitude of racial disparities in mean time to radiation therapy (TTRT) for Stage I-III non-small cell lung cancer patients across a variety of treatment facilities. Utilizing the United States National Cancer Database (NCDB), we determined differences in TTRT between different races and different treatment facilities. Concordant with past research, we found that non-White patients and patients treated at academic facilities, regardless of race, have longer mean TTRT, and that racial disparities in TTRT extend across all treatment facilities (all These findings shed light on the potential presence of and impact of structural racism on patients seeking cancer treatment, and the need for further investigation behind the reasonings behind longer TTI for non-White patients. To elucidate the real-world applicability of these results, further investigation into the societal determinants that perpetuate disparity in time to radiation therapy, and potential interventions in the clinical setting to improve cultural and racial sensitivity among healthcare professionals is recommended.
Identifiants
pubmed: 36081886
doi: 10.1089/heq.2022.0104
pii: 10.1089/heq.2022.0104
pmc: PMC9448516
doi:
Types de publication
Journal Article
Langues
eng
Pagination
603-609Informations de copyright
© Akhil Rekulapelli et al., 2022; Published by Mary Ann Liebert, Inc.
Déclaration de conflit d'intérêts
No competing financial interests exist.
Références
Lancet Oncol. 2015 Jun;16(6):630-7
pubmed: 25981812
J Clin Oncol. 2019 May 20;37(15):1316-1325
pubmed: 30943123
Ann Thorac Surg. 2015 Jun;99(6):1906-12; discussion 1913
pubmed: 25890663
Surg Oncol Clin N Am. 2012 Jul;21(3):417-37, viii
pubmed: 22583991
Mayo Clin Proc. 2008 May;83(5):584-94
pubmed: 18452692
JNCI Cancer Spectr. 2018 Apr 25;2(1):pky007
pubmed: 31360839
Am J Public Health. 2010 Apr 1;100 Suppl 1:S30-5
pubmed: 20147679
J Thorac Cardiovasc Surg. 2019 Apr;157(4):1670-1679.e4
pubmed: 30685165
Ann Surg. 2021 Jun 1;273(6):1023-1030
pubmed: 33234793
Int J Radiat Oncol Biol Phys. 2020 Oct 1;108(2):475-478
pubmed: 32890537
Clin Lung Cancer. 2021 Jan;22(1):e84-e97
pubmed: 33039348
J Immigr Minor Health. 2021 Jun;23(3):583-590
pubmed: 32691277
BJU Int. 2021 Jun;127(6):636-644
pubmed: 33166036
Cancer Epidemiol Biomarkers Prev. 2022 Jun 1;31(6):1243-1246
pubmed: 35642391
Clin J Oncol Nurs. 2021 Oct 1;25(5):17-24
pubmed: 34533532
Lung Cancer. 2017 Oct;112:156-164
pubmed: 29191588
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
PLoS One. 2019 Mar 1;14(3):e0213209
pubmed: 30822350
Curr Treat Options Oncol. 2018 Mar 12;19(4):17
pubmed: 29527638